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ABSTRACT
Objective To determine whether assessment tools for
non-randomised studies (NRS) address critical elements
that influence the validity of NRS findings for comparative
safety and effectiveness of medications.
Design Systematic review and Delphi survey.
Data sources We searched PubMed, Embase, Google,
bibliographies of reviews and websites of influential
organisations from inception to November 2019. In
parallel, we conducted a Delphi survey among the
International Society for Pharmacoepidemiology
Comparative Effectiveness Research Special Interest
Group to identify key methodological challenges for NRS
of medications. We created a framework consisting of
the reported methodological challenges to evaluate the
selected NRS tools.
Study selection Checklists or scales assessing NRS.
Data extraction Two reviewers extracted general
information and content data related to the prespecified
framework.
Results Of 44 tools reviewed, 48% (n=21) assess
multiple NRS designs, while other tools specifically
addressed case–control (n=12, 27%) or cohort studies
(n=11, 25%) only. Response rate to the Delphi survey
was 73% (35 out of 48 content experts), and a consensus
was reached in only two rounds. Most tools evaluated
methods for selecting study participants (n=43, 98%),
although only one addressed selection bias due to
depletion of susceptibles (2%). Many tools addressed the
measurement of exposure and outcome (n=40, 91%), and
measurement and control for confounders (n=40, 91%).
Most tools have at least one item/question on design-
specific sources of bias (n=40, 91%), but only a few
investigate reverse causation (n=8, 18%), detection bias
(n=4, 9%), time-related bias (n=3, 7%), lack of new-user
design (n=2, 5%) or active comparator design (n=0). Few
tools address the appropriateness of statistical analyses
(n=15, 34%), methods for assessing internal (n=15, 34%)
or external validity (n=11, 25%) and statistical uncertainty
in the findings (n=21, 48%). None of the reviewed
tools investigated all the methodological domains and
subdomains.
Conclusions The acknowledgement of major design-
specific sources of bias (eg, lack of new-user design,
lack of active comparator design, time-related bias,
depletion of susceptibles, reverse causation) and statistical

Strengths and limitations of this study
►► This is the first systematic review to investigate

whether existing tools adequately assess the validity
of non-randomised studies evaluating the comparative safety and effectiveness of medications.
►► Assessment tools were identified by searching
through multiple sources: relevant databases, grey
literature, websites of authoritative organisations,
bibliographies of previous systematic reviews and
experts’ suggestions.
►► The prepiloted framework adopted to evaluate the
completeness of the tools included all the main
methodological challenges suggested by an interdisciplinary (academia, industry and government
agencies) and international team of experts in the
field of pharmacoepidemiology and healthcare outcomes research.
►► Tools not published in English or that could not be
retrieved were omitted from this systematic review.
►► The search for tools in the grey literature might not
be comprehensive since it was performed through
only one browser.

assessment of internal and external validity is currently not
sufficiently addressed in most of the existing tools. These
critical elements should be integrated to systematically
investigate the validity of NRS on comparative safety and
effectiveness of medications.
Systematic review protocol and registration https://
osf.io/es65q.

INTRODUCTION
There are high expectations that real-world
data (RWD) and resultant real-world evidence
(RWE) will become a key source of information for the development process of pharmacological or biological therapies.1–3 The 21st
Century Cures Act and the sixth Prescription
Drug User Fee Act required the Food and
Drug Administration (FDA) to explore the
use of RWE and, consequently, well-designed
and conducted non-
randomised studies
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METHODS
The systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses statement.17 Systematic review protocol
and registration are available at https://osf.io/es65q.

manuals, tools to review study protocols, tools targeting
NRS of non-pharmacological interventions (eg, surgery)
or assessing only one or a few specific types of bias, and
tools not available in English language. In parallel, we
searched the same electronic databases for systematic
reviews of assessment tools of NRS. We then extracted
the references of the tools included in the systematic
reviews retrieved. We also performed a general search
through Google for grey literature and reviewed any
additional information from initiatives, programmes
or organisations. Full details on the search strategy are
reported in the supplement (online supplemental tables
S1 and S2). Three reviewers (ED, GS and LV) independently removed duplicates and reviewed titles and
reviewed publications or documents
abstracts of peer-
from the grey literature to select eligible tools. Discrepancies were resolved by consensus.
Delphi survey and prespecified framework
Concurrently, we performed a Delphi survey18 to reach a
consensus among content experts about the main methodological challenges (domains) that may threaten the
validity of NRS on comparative safety and effectiveness
of medications. The survey is available in the online
supplemental 2. The panel of experts involved members
of the SIG for CER of the ISPE. Detailed information on
the Delphi methods and results is reported in the online
supplemental 1.
Domains and subdomains indicated by the Delphi
respondents as major elements that can impact the
validity of NRS of medications were used to develop and
pilot a framework to evaluate the identified NRS tools. All
domains were considered equally important. A glossary of
terms used in the framework is reported in table 1.
Data extraction
Two reviewers (ED and LV) independently extracted general
information of the identified tools (first author or name of
the tool, year of publication or online availability of the most
updated version, type of tool, scope of the tool, NRS designs
evaluated and number of items) and content data related
to the prespecified domains of the framework. Discrepancies were resolved by consensus. We categorised the tools as
checklists, defined as itemised instruments (including questionnaires) developed to identify the presence or absence of
critical elements, or rating scales, defined as itemised instruments aimed to identify the performance of a study at each
critical element described in the tool, using a qualitative or
quantitative scale.

Systematic search and eligibility criteria
We searched PubMed and Embase from inception to
November 2019 to identify existing tools that investigated the validity of NRS, specifically case–control
and cohort design studies. We excluded guidelines or

Data synthesis
General characteristics of the identified tools were
summarised with means and SD, for continuous variables, and relative frequencies, for categorical variables.
The findings from the Delphi survey and the proportion
of tools assessing the prespecified elements of the framework were reported in terms of relative frequencies.
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(NRS) for expediting drug approvals.4 5 Similarly, one
of the goals of the European Medicines Agency (EMA)
Adaptive Pathways Initiative is to supplement clinical trial
data with RWD and to eventually produce RWE as part of
the approval process of new medications or indications.6
However, the growing demand for RWD has raised
concerns about the reliability of NRS to generate RWE.
Due to the inherent limitations of observational analyses,
the validity of NRS depends largely on the implementation of complex design and analytic methodologies.
In recent reports, both FDA and EMA emphasised the
need to plan and execute NRS following standards that
can ensure validity and reproducibility of RWE.7 8 Tools
that assess the validity of NRS can be useful instruments
for both researchers (eg, for authors and reviewers to
prevent publication of poor quality pharmacoepidemiological research) and other stakeholders who are involved
in clinical, managemental or economic decision making
(eg, to correctly inform guidelines and clinicians or to
guide resource allocation).
An analysis on the capability of existing tools to assess
the validity of NRS of comparative safety and effectiveness
of medications is currently lacking. Previously published
systematic reviews on assessment tools for NRS were
mostly descriptive and did not provide a critical evaluation of the tools content,9–13 investigated only a specific
type of bias14 or focused only on safety outcomes.15
Therefore, we conducted a systematic review to assess the
content of eligible tools for NRS of medications. There
is no agreement on an assessment framework for NRS of
pharmacological interventions. Thus, we performed a
Delphi survey among international experts in the field of
pharmacoepidemiology and health outcome research in order to
build consensus for the methodological challenges that
may threaten the validity of NRS of medications and that
should be evaluated by assessment NRS tools.
The main objective of this study was to determine
whether the retrieved NRS tools sufficiently address the
main methodological challenges recommended by the
experts. This study is part of a research project to develop
a framework for the synthesis of NRS and randomised
controlled trials (RCTs),16 led by the Comparative Effectiveness Research Special Interest Group (CER SIG) of
the International Society for Pharmacoepidemiology
(ISPE).

Open access

Term

Definition

Active comparator design A study design that compares the effect of the drug of interest with another drug used in clinical
practice instead of non-use.
Adjustment for causal
Adjustment for an intermediate variable (or a descending proxy for an intermediate variable) on a
intermediaries
causal path from exposure to outcome.
Case–control design

A study design in which cases (patients with outcomes) are identified and compared with controls
(patients without outcomes) with respect to the exposure of interest.

Cohort design

A study design in which a group of patients (a cohort) is identified and followed to ascertain the
occurrence of an outcome.

Confounding

A mixing of effects that arises when patients with different baseline risks are compared; the
resulting effect measure is a mix of drug effects and risk factor effects.

Depletion of susceptibles Selection bias that occurs when the initiation of exposure to a drug is associated with an early
increased incidence rate of the study outcome, followed by a decreased incidence rate with longer
duration of exposure (eg, users of new drugs are compared with users of older drugs).
Detection or surveillance
bias

Bias that occurs when the degree of outcome surveillance (or an associated symptom) is related to
exposure and is differential among the exposure groups.

Immortal time bias

Time-related bias that derives from including a period of follow-up during which, by design,
outcomes cannot occur.

Time-window bias

Time-related bias, in the context of a case–control study nested in a cohort, that derives from the
use of time-windows of different lengths between cases and controls to define time-dependent
exposures.

Incorrect outcome model Misspecification of a statistical model that leads to biased outcome results. Common causes are
specification
omission of a relevant variable, inclusion of an unnecessary variable, adopting the wrong functional
form, incorrect specification of the error term, uncertainty about what the true model is and
reciprocal causation.
Loss to follow-up bias

Bias that occurs when there is difference in retention during the follow-up period after enrolment
that are related to exposure status and outcome.

New-user design

A study design that starts following patients at the time they initiate a new drug (also known as
incident-user design)

Non-contemporaneous
comparator bias

Bias generated by differences in the timing of selection of comparator group(s) within a study
influence exposures and outcomes resulting in biased estimates.

Reverse causation (or
reverse causality)

Bias due to direction of cause and effect contrary to a common presumption, or a two-way causal
relationship between exposure and outcome.

Recall bias

Bias that occurs when participants do not remember previous events or experiences accurately or
omit details (not for claims-based studies).
Bias that occurs when selection of participants or follow-up time is related to both intervention
and outcome (eg, prevalent users of a drug are compared with non-users or incident users). Our
framework has a separate subdomain that refers to selection bias due to lack of generalisability,
applicability or transferability to patients who were excluded from the study.

Selection bias

RESULTS
Overview of tools
Of 44 tools that met our eligibility criteria,19–52 20 (45%)
were identified through the database search of peer-
reviewed literature and 24 (55%) through the general
online search and other sources (online supplemental
figure S1 and table S3). Characteristics of the tools are
shown in tables 2 and 3. The number of items across all
tools ranged from 5 to 54, with a median of 13.5 (IQR
10.3–22). Only three tools were designed to specifically
address studies on the comparative safety and effectiveness of pharmacological interventions: one published
in 1994 by Cho and Bero,46 the The Good ReseArch
for Comparative Effectiveness (GRACE) checklist and
D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

the International Society for Pharmacoeconomics
and Outcomes Research – Academy of Managed Care
Pharmacy – National Pharmaceutical Council (ISPOR-
AMCP-NPC) tool, both published in 2014.25 26
Tool formats and scopes
Most of the tools were checklists (n=35, 80%), and 13
checklists included a final section to elaborate a summary
judgement of the study appraisal (37%). The remaining
tools were scales (n=9, 20%), and six of them provided a
section for a summary judgement (67%).
Thirty-five tools (80%) were designed as critical appraisal
tools for different scopes (eg, assessing the quality of NRS
included in a systematic review, screening eligible NRS to
3
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Table 1 Glossary of terms

Open access

Scope of the tool

Study design
evaluated

tems

Checklist

Critical appraisal and reporting

NRS

21

Rating scale+summary judgement

Critical appraisal

Coh (+RCTs), CC Coh (+RCTs) 21, CC 18

Tool identified*

Year

Type of tool

RELEVANT

2019

RAMboMAN - GATE-EPIQ

2019

MMAT

2018

Checklist

Critical appraisal

NRS

CASP

2018

Checklist

Critical appraisal

Coh, CC

Coh 12, CC 11

5

SURE

2018

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 13, CC 11

JBI

2017

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 11, CC 10

ROBINS-I

2016

Checklist+summary judgement

Critical appraisal

NRS

34 (+8 optional
question)

ISPOR-AMCP-NPC†

2014

Checklist+summary judgement

Critical appraisal

Coh CC

32

GRACE†

2014

Checklist+summary judgement

Critical appraisal

Coh CC

11

NIH–NHLBI

2014

Checklist+summary judgement

Critical appraisal

Coh (+CSS), CC

Coh (+CSS) 14, CC 12

HEBW

2014

Checklist+summary judgement

Critical appraisal

Coh

18

RoBANS

2013

Rating scale

Critical appraisal

NRS

6

RTI-Item Bank

2013

Checklist

Critical appraisal

NRS

13

Newcastle-Ottawa

2013

Rating scale +summary judgement

Critical appraisal

Coh, CC

Coh 8, CC 8

SIGN - V.3.0

2012

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 14, CC 11

Montreal

2011

Checklist

Critical appraisal

Coh CC (+RCTs) 10

EPHPP

2011

Rating scale

Critical appraisal

Coh CC (+RCTs) 17

STROBE – V.4

2007

Checklist

Reporting

Coh, CC

Coh 22, CC 22

TREND

2004

Checklist

Reporting

NRS

22

Margetts

2002

Checklist

Reporting

Coh CC

11

Zaza

2000

Checklist

Critical appraisal

Coh CC

15

Downs-Black

1998

Rating scale

Critical appraisal and reporting

Coh CC (+RCTs) 27

Elwood

1998

Checklist

Critical appraisal

Coh CC (+RCTs) 20

Hadorn

1996

Checklist

Critical appraisal

Coh (+RCTs)

London

1996

Checklist

Critical appraisal

Coh CC

Avis

1994

Rating scale+summary judgement

Critical appraisal and reporting

Coh CC (+RCTs) 24

Durant

1994

Checklist

Critical appraisal

CC

Levine

1994

Checklist

Critical appraisal

Coh CC (+RCTs) 10

Gyorkos

1994

Checklist

Critical appraisal

Coh, CC

Coh 6, CC 5

Cho†

1994

Rating scale+summary judgement

Critical appraisal

NRS (+RCTs)

24

COEH

1991

Checklist

Critical appraisal

NRS

54

Fowkes-Fulton

1991

Checklist+summary judgement

Critical appraisal and reporting

NRS (+RCTs)

Lichtenstein

1987

Checklist

Critical appraisal

CC

7
33
23

6
20

Gardner

1986

Checklist

Critical appraisal

NRS

12

Horwitz

1979

Checklist

Critical appraisal and reporting

CC

12

Nine tools from our bibliographic search provided two separate instruments to assess cohort or case–control studies. Thus, the overall number of included records
is 35, while the number of included assessment tools is 44.
*Tool name or first author name, if the tool does not have an assigned name, and it was published in peer-review journals.
†Tool developed to assess NRS on the comparative safety and effectiveness of medications.
CASP, The Critical Appraisals Skills Programme; CC, case–control study; COEH, Centre for Occupational and Environmental Health of The University of Manchester;
Coh, cohort study; CSS, cross-sectional study; EPHPP, Effective Public Health Practice Project Quality Assessment Tool; GRACE, The Good ReseArch for
Comparative Effectiveness; HEBW, Health Evidence Bulletins Wales; ISPOR-AMCP-NPC, International Society for Pharmacoeconomics and Outcomes Research
– Academy of Managed Care Pharmacy – National Pharmaceutical Council; JBI, The Joanna Briggs Institute; MMAT, Mixed Methods Appraisal Tool; NIH–NHLBI,
The National Institute of Health - The National Heart, Lung, and Blood Institute; NRS, non-randomised studies; RAMboMAN, GATE-EPIQ, Recruitment Allocation
Maintenance blind objective Measurements Analyses, Graphic Approach To Epidemiology – Effective Practice, Informatics and Quality Improvement; RCTs,
randomised controlled trials; RELEVANT, The REal Life EVidence AssessmeNt Tool; RoBANS, Risk of Bias Assessment tool for Non-randomized Studies; ROBINS-I,
Risk Of Bias In Non-randomized Studies of Interventions; RTI-Item Bank, Research Triangle Institute Item Bank; SIGN, The Scottish Intercollegiate Guidelines
Network; STROBE, STrengthening the Reporting of OBservational studies in Epidemiology; SURE, Specialist Unit for Review Evidence; TREND, Transparent
Reporting of Evaluations with Non-randomized designs.

include in systematic reviews to support clinical guidelines,
supporting peer-review processes or, more general, allowing
readers to interpret NRS results critically). Four tools (9%)

were developed to assess the quality of reporting and were
mainly intended for researchers. Five other tools (11%)
combined elements of both critical appraisal and quality

4
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Table 2 Individual characteristics of the tools included in the systematic review
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Characteristics
Publication year, n (%)
 1979–1989

All,
n=44

Cohort*,
n=11

Case–control,
n=12

NRS†,
n=21

3 (7)

0 (0)

2 (17)

1 (5)

12 (27)

2 (18)

2 (17)

8 (38)

 2000–2009

5 (11)

1 (9)

1 (8)

3 (14)

 2010–2019

24 (55)

8 (73)

7 (58)

9 (43)

 Checklist

22 (50)

4 (36)

6 (50)

12 (57)

 Checklist+summary judgement

13 (30)

5 (45)

4 (33)

4 (19)

 Rating scale

3 (7)

0 (0)

0 (0)

3 (14)

 Rating scale+summary judgement

6 (14)

2 (18)

2 (16)

2 (9)

 1990–1999

Type of tool, n (%)

Scope of the tool, n (%)
 Critical appraisal

35 (80)

9 (81)

10 (83)

16 (76)

 Reporting

4 (9)

2 (18)

1 (8)

1 (5)

 Critical appraisal and reporting

5 (11)

0 (0)

1 (8)

4 (19)

Tools designed for CER, n (%)
Number of items, median (IQR)

3 (7)
13 (10.3–21.8)

0 (0)
13 (9.5–16)

0 (0)
11.5 (10.8–18.5)

3 (14)
17 (11–24)

*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross-sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross-
sectional studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of
RCTs.
CER, Comparative Effectiveness research; NRS, non-randomised studies; RCTs, randomised controlled trials.

reporting and were for a more general audience (both
researchers and readers) (tables 2 and 3).
Study designs addressed
Twenty-one tools (48%) were developed to assess multiple
NRS designs (11 targeted cohort and case–control studies
and 10 others addressed also other NRS designs or did not
specify them). Other tools specifically addressed case–control
(n=12, 27%) or cohort studies (n=11, 25%). Ten tools (23%)
were designed to assess also RCTs.

Measurement of exposure, outcomes, covariates and follow-up
Forty-two tools (95%) had at least one item assessing the
definition and measurement of exposure, outcome, covariates and follow-up. Assessment of exposure and outcome was
widely reported by the tools (n=40, 91%), while definition
and measurement of covariates (n=12, 27%) or follow-up
(n=17, 39%) were less often addressed (with the exception
for tools addressing follow-up in cohort studies only, n=9,
82%) (table 4 and online supplemental figure S4).

Methods for selecting participants
Nearly all tools assessed methods for selecting study participants to correct selection bias (n=43, 98%). Specifically,
almost half of the tools included items related to sampling
strategies (n=19, 43%), the definition of inclusion and exclusion criteria (n=27, 61%) and the generalisability of participants (ie, attempts to achieve a sample of participants that
represents the target population) (n=21, 48%), while only
one tool addressed the depletion of susceptibles (n=1, 2%)
(table 4 and online supplemental figure S3).

Design-specific sources of bias
Design-specific sources of bias (excluding selection bias which
was investigated in ‘Methods for selecting participants’) were
assessed by 91% of the tools (n=40) and generally included
loss to follow-up bias (n=22, 50%), observer or interviewer
bias (n=11, 25%), reverse causation bias (n=8, 18%), recall
bias (n=6, 14%) and non-contemporaneous comparator bias
(n=6, 14%). A few or no tools assessed detection or surveillance bias (n=4, 9%), time-related bias, such as immortal
person-time bias or time-window bias (n=3, 7%), and biases
due to lack of new-user design (n=2, 5%) or active comparator design (n=0). Other tools reported only a general item/
question on the risk of bias (n=9, 20%), without any reference to a specific type of bias.
Tools specifically for cohort studies addressed more
frequently loss to follow-up (n=9, 82%) and reverse causation
biases (n=5, 45%) compared with the other tools, while
tools for case–control studies addressed mostly recall (n=4,
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Tool elements
The response rate of the Delphi survey was 73% (35 respondents out of 48 members). Detailed results are reported in
the online supplemental figure S2. Domains and subdomains indicated by the respondents as major elements that
can impact the validity of NRS of medications are reported in
the first column of table 4.
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Table 3 General characteristics of the assessment tools included in the systematic review
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Domains

Cohort tools*,
n=11

Case–control
tools, n=12

NRS tools†,
n=21

Total,
n=44

1. Methods for selecting participants, n (%)

11 (100)

12 (100)

20 (95)

43 (98)

 Sampling strategies to correct selection bias

4 (36)

6 (50)

9 (42)

19 (43)

 Inclusion and exclusion criteria of target population

6 (55)

8 (67)

13 (61)

27 (61)

 Depletion of susceptibles

1 (9)

0 (0)

0 (0)

1 (2)

 External validity of target population

6 (55)

6 (50)

9 (43)

21 (48)

 Others‡

11 (100)

12 (100)

18 (86)

41 (93)

2. Measurement of exposure, outcomes, covariates and follow-up, n (%)§

11 (100)

12 (100)

19 (90)

42 (95)

 Measurement of exposure§

11 (100)

11 (92)

18 (81)

40 (91)

 Measurement of outcomes§

11 (100)

11 (92)

18 (81)

40 (91)

 Measurement of covariates

4 (36)

4 (33)

4 (19)

12 (27)

 Measurement of follow-up

9 (82)

3 (25)

5 (24)

17 (39)

11 (100)

10 (83)

19 (90)

40 (91)

0 (0)

0 (0)

3. Design-specific sources of bias, n (%)
 New-user design

2 (10)

2 (5)

 Active comparator design

0 (0)

0 (0)

0 (0)

0 (0)

 Immortal time bias or time-window bias

0 (0)

0 (0)

3 (14)

3 (7)

 Detection or surveillance bias

1 (9)

2 (17)

1 (5)

4 (9)

 Loss to follow-up bias

9 (82)

1 (8)

12 (57)

22 (50)

 Non-contemporaneous comparator bias

0 (0)

1 (8)

5 (24)

6 (14)

 Reverse causation

5 (45)

1 (8)

2 (10)

8 (18)

 Recall bias¶

1 (9)

4 (33)

1 (5)

6 (14)

 Interviewer or observer bias¶

1 (9)

3 (25)

7 (35)

11 (25)

 Ascertainment bias¶

0 (0)

1 (8)

1 (5)

2 (5)

 General item/question on bias¶

3 (27)

3 (25)

3 (14)

9 (20)

 Other biases**

0 (0)

2 (17)

5 (24)

7 (16)

11 (92)

18 (86)

40 (91)

4. Confounding, n (%)

11 (100)

 Study design used to minimise confounding

6 (55)

7 (58)

13 (62)

26 (59)

10 (91)

10 (83)

18 (86)

38 (86)

 Potential unmeasured confounding addressed in the analysis (eg, proxy
analysis and IV analysis)

1 (9)

1 (8)

3 (14)

5 (11)

5. Lack of appropriateness of statistical analyses (with specific mention of
overadjustment and/or incorrect outcome model specification), n (%)

2 (18)

3 (25)

10 (48)

15 (34)

6. Methods for assessing statistical uncertainty in the findings (eg, CIs
reported for each analysis), n (%)

7 (64)

6 (50)

8 (38)

21 (48)

7. Methods for assessing internal validity (eg, sensitivity analysis addressing
potential confounding, measurement errors or other biases), n (%)

3 (27)

3 (25)

9 (43)

15 (34)

8. Methods for assessing external validity (eg, post hoc subgroup analysis
and comparison with other populations), n (%)

4 (36)

3 (25)

4 (19)

11 (25)

 Confounders measured and included in statistical analyses

*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross-sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross-sectional
studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of RCTs.
‡'Others’ refers to items not included in our evaluation framework but included in the reviewed tools to investigate selection bias (eg, population
characteristics sufficiently described to determine the applicability of the research question, sample size justification and power description, and
ethical considerations).
§Items or questions on exposure misclassification and/or outcome misclassification are counted in this domain and relative subdomains.
¶Design-specific biases not included in the evaluation framework but addressed by the reviewed tools.
**Other design-specific biases not included in the evaluation framework but addressed by a few tools (eg, bias due to missing data, patients'
blinding, different length of follow-up between groups, Berkson’s bias and protopathic bias).
IV, instrumental variable; NRS, non-randomised studies; RCTs, randomised controlled trials.

33%) and observer biases (n=3, 25%). Tools for multiple
NRS covered commonly loss to follow-up (n=12, 57%) and
interviewer or observer biases (n=7, 35%) (table 4 and online
supplemental figure S5).

Confounding
Forty tools (91%) included at least one item or question
related to confounding. Specifically, 26 tools (59%) searched
whether study design was planned in a way to minimise
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Table 4 Methodological challenges addressed by the included assessment tools

Open access

Appropriateness of statistical analyses, external and internal
validity
One-third of the tools (n=14, 32%) assessed the appropriateness of statistical analyses, although most of them did not
explicitly mention overadjustment of causal intermediates
and/or incorrect outcome model specification. Almost half
(n=21, 48%) included methods for measuring uncertainty
in the findings. Few tools addressed methods for evaluating internal (n=15, 34%) or external validity (n=11, 25%)
(table 4 and online supplemental figure S7 in the online
supplement).
These results were mostly consistent across the three
different types of design addressed, cohort only, case–
control only and multiple NRS, except for the assessment of follow-up (domain 2) and several design-specific
sources of biases (domain 3) already mentioned above
(table 4). None of the reviewed tools covered all the main
domains and subdomains as identified by the CER SIG
and listed in table 4.
Results for each selected tool on the proportions of
items/questions that investigate the prespecified domains
are shown in the online supplemental figures S8–S11.

DISCUSSION
In this systematic review, we identified assessment tools
evaluating the validity of NRS on comparative safety and
effectiveness of medications. Of 44 tools included, only
three were specifically designed to assess NRS of pharmacological interventions.25 26 46
Main findings
Overall, we found that existing tools assessed most of the
methodological challenges identified by the domains of
the CER SIG framework, but critical elements were often
insufficiently addressed. For example, although many
tools assessed the risk of selection bias, only half of them
explicitly investigated sampling strategies and considered a prespecification of inclusion/exclusion criteria.
Even more surprising was that only one tool explored the
potential for selection bias due to depletion of patients
that are susceptible to the outcome. This cohort-based
phenomenon can occur when new users of a medication
are depleted of all susceptible subjects to the outcome,
documenting an increased incidence rate of the outcome
in an early stage, followed by a decreased rate with a
longer duration of exposure.53 Depletion of susceptibles
is an important source of bias to account for when evaluating effects of new medications in incident users and can
significantly undermine the validity of the results.53
Similarly, many tools investigated misclassification or
information bias of exposure and outcome. However, only
about one-third assessed definition and measurement of
D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

covariates, and less than one-fourth of the case–control
and multiple NRS designs tools assessed information on
follow-up definition. Again, these are common causes of
bias and should be integrated in tools that investigate the
validity of NRS.
Design-specific sources of bias was a critical domain.
Although overall 91% of the tools had at least one item/
question investigating biases due to an inappropriate
study design, only Risk Of Bias In Non-
randomized
Studies of Interventions (ROBINS-
I) and the GRACE
checklist addressed bias due to lack of new-user design
and time-related bias (ie, immortal person-time bias or
time-window bias), while no tools investigated bias due
to lack of active comparator design. Since these biases
can independently lead to major methodological flaws
(defined as elements that by themselves can significantly
compromise the validity of the results), their assessment
must be included in appraisal tools for NRS of pharmacological interventions. For example, recent evidence on
NRS of glucose-lowering medications reported that only
one-fourth of the studies adopted a new-user design and
less than half used an active comparator.54 In the same
example, potential for time-
related bias was detected
in more than two-
third of the studies.54 Integrating
the evaluation of these major methodological flaws in
existing tools and recommending the use of these tools
before publication can increase awareness in the clinical
research community with respect to main design-specific
biases. This can ultimately decrease the amount of NRS
with invalid findings on the safety or effectiveness of
medications.
A high percentage of tools evaluated whether
confounders were appropriately measured, controlled
for in the analysis and considered in the study design.
However, very few tools included at least one item/question on whether potential unmeasured confounding
had been considered in the analysis or interpretation of
findings.
One-third of the tools checked the appropriateness of
statistical analyses, but most omitted specific reference
to common flaws such as overadjustment or incorrect
outcome model specification. Similarly, only one-third of
the tools assessed internal validity (eg, through sensitivity
analysis to address potential confounding, measurement
errors or other biases), and only one-
fourth assessed
external validity (eg, post hoc subgroup analysis and
comparison with other populations).
Implications for practice and research
While recently published tools such as The Critical Appraisals Skills Programme checklist,21 ISPOR-
AMCP-NPC,25 Recruitment Allocation Maintenance
blind objective Measurements Analyses,19 GRACE26
and ROBINS-I24 are among the most complete tools,
addressing several of the critical elements underlined by
the ISPE CER SIG, they all had limitations in the acknowledgement of two or more major methodological challenges (eg, selection bias for depletion of susceptibles,
7
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confounding, 38 (86%) whether confounders were measured
and included in the analyses and only five whether potential
unmeasured confounding was assessed in the sensitivity analyses (11%) (table 4 and online supplemental figure S6).

Open access
the comparative safety and effectiveness of medications.
Previously published systematic reviews on assessment
tools for NRS were not specifically focused on pharmacological interventions,9 10 included randomised study
designs11–13 or investigated only a specific type of bias.14
One systematic review of NRS tools for medications
focused only on safety outcomes, and it is now outdated
since published in 2012.15 Our systematic review has
multiple strengths: authors reviewed the results of the
searches independently following a predefined protocol;
the framework for data extraction was developed based
on inputs of worldwide experts in the field of pharmacoepidemiology and healthcare outcomes research
coming from different backgrounds (academia, industry
and governmental agency) and different countries, and
it included the most updated versions of the identified
tools. This review also has limitations. Search for tools in
the grey literature might not be comprehensive since it
was performed through only one browser. The search was
also restricted to tools published in English and excluded
identified tools that could not be retrieved.

CONCLUSION
In this systematic review, we found that available tools for
NRS assessment failed to provide a comprehensive assessment of major methodological aspects that can affect the
validity of NRS on the comparative safety and effectiveness of medications. Specifically, major aspects such as
lack of new-user design, active comparator design, time-
related bias (ie, immortal time bias and time-
window
bias) and statistical assessment of internal validity remain
poorly covered. Including these critical elements into
existing tools may provide a more accurate instrument
to evaluate NRS of pharmacological interventions and
increase awareness in the clinical research community
about major addressable flaws in pharmacoepidemiology.
This may improve the validity of NRS on the comparative
safety and effectiveness of medications and reduce the
publication of studies with unreliable findings.

Strengths and limitations
To our knowledge, this is the first systematic review that
investigated whether existing tools adequately assess the
validity of cohort and case–control studies evaluating
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immortal-
time bias or window-
time bias, lack of new-
user design, lack of active comparator design, reverse
causation bias and adjustment for causal intermediaries). Assessment tools can be powerful instruments for
researchers, authors, reviewers of scientific journals or
readers, helping to identify the main limitations of a study
and to correctly interpret the results, to acknowledge
major methodological flaws and, ultimately, to prevent
publication of studies with invalid findings.
Furthermore, other decision makers, such as clinicians,
guideline developers and payers or investors, can benefit
from instruments that help to ensure the validity of NRS
findings. RCTs can be an insufficient source of evidence
for decisions on pharmaceutical interventions.55 56 Despite
well-designed and adequately powered RCTs being considered the ‘gold standard’ of the clinical research paradigm,
they can often be too time intensive and money intensive. Trials are often relatively small, focus on short-term
efficacy and safety in a controlled clinical environment,
using surrogate outcomes or under-representing high-risk
populations that can be most likely the target on the new
medications in the real-world setting.55 56 Trials might also
not record treatments taken outside the study protocol.47
Additionally, patients volunteered to participate in a
trial are usually very motivated and so more adherent
to therapy compared with the real-world population.56
NRS based on RWD can help to address these issues and
could be supplement the evidence from RCTs to provide
a more complete picture on the effectiveness of pharmaceutical interventions in less controlled environments.
NRSs have the advantages to investigate large-scale populations, high-risk subpopulations, rare exposures, diseases
or outcome, and long-term outcomes or other delayed
health effects at low costs and rapidly.55 56 Moreover, since
RWD are often collected for intents unrelated to research
objectives (mainly administrative), biases such as recall
bias, interviewer bias, non-response bias and bias for loss
to follow-
up are reduced or eliminated.55 Thus, since
RWE derived by NRS contribute significantly to generate
evidence of comparative effectiveness research of medications, our synthesis can help numerous stakeholders to
evaluate whether the NRS considered are valid enough to
guide decision making.
Although checklists have been previously suggested
for reviewing the risk of bias of general NRS,57 we cannot
strongly recommend a specific tool for NRS on comparative analyses of medications. As already mentioned, items
or questions that address all those methodological flaws
must be integrated in the existing tools. Based on our
findings, most recent and comprehensive tools such as
ROBINS-I24 and GRACE26 assessed a higher number of
major methodological elements and could therefore be
prioritised in this endeavour.

Open access
Real World Evidence Sciences, Visible Analytics Ltd, Oxford, UK

Twitter Andrew R. Zullo @andrewzullo and Thomas P. A. Debray @TPA_Debray
Acknowledgements We are grateful to all the members of the International
Society for Pharmacoepidemiology Comparative Effectiveness Research Special
Interest Group for their participation to the Delphi survey.
Contributors ED was involved in substantial contributions to the conception and
design, acquisition of data, analysis and interpretation of the data; drafting the
article and revising it for intellectual content; and final approval of the version
to be published. LV, GS and TD were involved in substantial contributions to the
conception and design, acquisition of data, analysis and interpretation of the data;
revising the article for intellectual content; and final approval of the version to be
published. EP and JF were involved in substantial contributions to the conception
and design, analysis and interpretation of the data; revising the article for
intellectual content; and final approval of the version to be published. DB, JL, DM,
HY, XW and ARZ were involved in substantial contributions to the conception and
design, and interpretation of the data; revising the article for intellectual content;
and final approval of the version to be published.
Funding This project has received funding from the European Union’s Horizon
2020 research and innovation programme under ReCoDID grant agreement No
825746.
Competing interests DB is an employee of Takeda. ARZ has received salary
support from Sanofi Pasteur through a grant to Brown University unrelated to
the current work. TD provides consulting services via Smart Data Analysis and
Statistics. GS discloses being employed by Visible Analytics Ltd.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the
article or uploaded as supplemental information.
Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any opinions or recommendations discussed are solely those
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and
responsibility arising from any reliance placed on the content. Where the content
includes any translated material, BMJ does not warrant the accuracy and reliability
of the translations (including but not limited to local regulations, clinical guidelines,
terminology, drug names and drug dosages), and is not responsible for any error
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iDs
Elvira D'Andrea http://orcid.org/0000-0002-5263-3964
Elisabetta Patorno http://orcid.org/0000-0002-8809-9898
Dimitri Bennett http://orcid.org/0000-0002-8387-9342
Thomas P. A. Debray http://orcid.org/0000-0002-1790-2719
Grammati Sarri http://orcid.org/0000-0001-5536-8038

REFERENCES

1 Eichler H-G, Bloechl-Daum B, Broich K, et al. Data rich, information
poor: can we use electronic health records to create a learning
healthcare system for pharmaceuticals? Clin Pharmacol Ther
2019;105:912–22.
2 Baumfeld Andre E, Reynolds R, Caubel P, et al. Trial designs using
real-world data: the changing landscape of the regulatory approval
process. Pharmacoepidemiol Drug Saf 2020;29:1201–12.
3 Yuan H, Ali MS, Brouwer ES, et al. Real-World evidence: what it
is and what it can tell us according to the International Society
for pharmacoepidemiology (IspE) comparative effectiveness
research (CER) special interest group (SIG). Clin Pharmacol Ther
2018;104:239–41.
4 United States Food and Drug Administration. PDUFA VI: fiscal years
2018‐2022. Available: https://www.fda.gov/ForIndustry/UserFees/
PrescriptionDrugUserFee/ucm446608.htm [Accessed 9 Jul 2020].

D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

5 Senate and House of Representatives of the United States of
America. 21st century cures act. Available: https://www.congress.
gov/114/plaws/publ255/PLAW‐114publ255.pdf [Accessed 9 Jul
2020].
6 European Medicines Agency. Adaptive pathways. Available: https://
www.ema.europa.eu/en/human‐regulatory/research‐development/
adaptive‐pathways
7 United States Food and Drug Administration. Submitting documents
utilizing real‐world data and real‐world evidence to FDA for drugs
and biologics. Available: https://www.fda.gov/regulatory‐information/
search‐fda‐guidance‐documents/submitting‐documents‐utilizing‐
real‐world‐data‐and‐real‐world‐evidence‐fda‐drugs‐and‐biologics
8 European Medicines Agency. HMA‐EMA joint big data Taskforce—
summary report. Available: https://www.ema.europa.eu/documents/
minutes/hma/ema‐joint‐task‐force‐big‐data‐summary‐report_en.pdf
[Accessed 9 Jul 2020].
9 Quigley JM, Thompson JC, Halfpenny NJ, et al. Critical appraisal of
nonrandomized studies-A review of recommended and commonly
used tools. J Eval Clin Pract 2019;25:44–52.
10 Sanderson S, Tatt ID, Higgins JPT. Tools for assessing quality and
susceptibility to bias in observational studies in epidemiology: a
systematic review and annotated bibliography. Int J Epidemiol
2007;36:666–76.
11 Katrak P, Bialocerkowski AE, Massy-Westropp N, et al. A systematic
review of the content of critical appraisal tools. BMC Med Res
Methodol 2004;4:22.
12 Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality
assessment tools for preclinical and clinical studies, systematic
review and meta-analysis, and clinical practice guideline: a
systematic review. J Evid Based Med 2015;8:2–10.
13 Morton SC, Costlow MR, Graff JS, et al. Standards and guidelines
for observational studies: quality is in the eye of the beholder. J Clin
Epidemiol 2016;71:3–10.
14 Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of
reporting biases in studies and syntheses of studies: a systematic
review. BMJ Open 2018;8:e019703.
15 Neyarapally GA, Hammad TA, Pinheiro SP, et al. Review of quality
assessment tools for the evaluation of pharmacoepidemiological
safety studies. BMJ Open 2012;2:e001362.
16 Sarri G, Patorno E, Yuan H, et al. Framework for the synthesis
of non-randomised studies and randomised controlled trials: a
guidance on conducting a systematic review and meta-analysis
for healthcare decision making. BMJ Evid Based Med 2020.
doi:10.1136/bmjebm-2020-111493. [Epub ahead of print: 09 Dec
2020].
17 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that
evaluate healthcare interventions: explanation and elaboration. BMJ
2009;339:b2700.
18 Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi
survey technique. J Adv Nurs 2000;32:1008–15.
19 School of Population Health. EPIQ (effective practice, informatics
and quality improvement). faculty of medical and health sciences,
University of Auckland, 2019. Available: https://www.fmhs.
auckland.ac.nz/en/soph/about/our-departments/epidemiology-and-
biostatistics/research/epiq.html [Accessed 9 Jul 2020].
20 Hong QN, Pluye P, bregues S F, et al. Mixed Methods Appraisal
Tool (MMAT), version 2018. Registration of Copyright (#1148552),
Canadian Intellectual Property Office, Industry Canada.
21 Critical Appraisal Skills Programme. CASP Cohort Study. Checklist
[online], 2018. Available: https://casp-uk.net/casp-tools-checklists/
[Accessed 9 Jul 2020].
22 Specialist Unit for Review Evidence (SURE). Questions to assist with
the critical appraisal of cohort studies, 2018. Available: http://www.
cardiff.ac.uk/insrv/libraries/sure/checklists.html [Accessed 9 Jul
2020].
23 The Joanna Briggs Institute. System for the unified management of
the review and assessment of information (SUMARI), 2017. Available:
http://joannabriggs-webdev.org/research/critical-appraisal-tools.html
[Accessed 9 Jul 2020].
24 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for
assessing risk of bias in non-randomised studies of interventions.
BMJ 2016;355:i4919.
25 Berger ML, Martin BC, Husereau D, et al. A questionnaire to assess
the relevance and credibility of observational studies to inform health
care decision making: an ISPOR-AMCP-NPC good practice Task
force report. Value Health 2014;17:143–56.
26 Dreyer NA, Velentgas P, Westrich K, et al. The grace checklist
for rating the quality of observational studies of comparative
effectiveness: a tale of hope and caution. J Manag Care Spec Pharm
2014;20:301–8.

9

BMJ Open: first published as 10.1136/bmjopen-2020-043961 on 24 March 2021. Downloaded from http://bmjopen.bmj.com/ on March 31, 2021 by guest. Protected by copyright.

13

Open access

10

41 Hadorn DC, Baker D, Hodges JS, et al. Rating the quality of evidence
for clinical practice guidelines. J Clin Epidemiol 1996;49:749–54.
42 Ashby J, Carlo G, Cohen SM. Principles for evaluating epidemiologic
data in regulatory risk assessment. federal focus, incorporated.
Washington, DC, 1996. http://www.fedfocus.org/science/london-
principles.html
43 DuRant RH. Checklist for the evaluation of research articles.
J Adolesc Health 1994;15:4–8.
44 Levine M, Walter S, Lee H, et al. Users' guides to the medical
literature. IV. How to use an article about harm. evidence-based
medicine Working group. JAMA 1994;271:1615–9.
45 Gyorkos TW, Tannenbaum TN, Abrahamowicz M, et al. An approach
to the development of practice guidelines for community health
interventions. Can J Public Health 1994;85(Suppl 1):S8–13.
46 Cho MK, Bero LA. Instruments for assessing the quality of drug
studies published in the medical literature. JAMA 1994;272:101–4.
47 Centre for Occupational and Environmental Health. Critical
appraisal. School of epidemiology and health sciences, University
of Manchester, 2003. Available: http://research.bmh.manchester.
ac.uk/epidemiology/COEH/undergraduate/specialstudymodules/
criticalappraisal/ [Accessed 9 Jul 2020].
48 Fowkes FG, Fulton PM. Critical appraisal of published research:
introductory guidelines. BMJ 1991;302:1136–40.
49 Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading
case-control studies. J Chronic Dis 1987;40:893–903.
50 Gardner MJ, Machin D, Campbell MJ. Use of check Lists in
assessing the statistical content of medical studies. Br Med J
1986;292:810–2.
51 Horwitz RI, Feinstein AR. Methodologic standards and
contradictory results in case-control research. Am J Med
1979;66:556–64.
52 Campbell JD, Perry R, Papadopoulos NG, et al. The real life evidence
assessment tool (relevant): development of a novel quality assurance
asset to rate observational comparative effectiveness research
studies. Clin Transl Allergy 2019;9:21.
53 Suissa S. Immortal time bias in pharmaco-epidemiology. Am J
Epidemiol 2008;167:492–9.
54 Bykov K, He M, Franklin JM, et al. Glucose-Lowering medications
and the risk of cancer: a methodological review of studies based on
real-world data. Diabetes Obes Metab 2019;21:2029–38.
55 Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled
trials: a critical comparison of trials with nonrandomized studies.
Hepatology 2006;44:1075–82.
56 Schneeweiss S, Avorn J. A review of uses of health care utilization
databases for epidemiologic research on therapeutics. J Clin
Epidemiol 2005;58:323–37.
57 Schünemann HJ, Cuello C, Akl EA, et al. Grade guidelines: 18. How
ROBINS-I and other tools to assess risk of bias in nonrandomized
studies should be used to rate the certainty of a body of evidence.
J Clin Epidemiol 2019;111:105–14.

D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

BMJ Open: first published as 10.1136/bmjopen-2020-043961 on 24 March 2021. Downloaded from http://bmjopen.bmj.com/ on March 31, 2021 by guest. Protected by copyright.

27 The National Institutes of Health and The National Heart, Lung,
and Blood Institute (NIH-NHLBI). Study quality assessment tools.
Available: https://www.nhlbi.nih.gov/health-topics/study-quality-
assessment-tools [Accessed 9 Jul 2020].
28 Health Evidence Bulletin. Questions to assist with the critical
appraisal of an observational study eg cohort, case-control, cross-
sectional. Wales: HEB, 2014.
29 Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk
of bias for nonrandomized studies showed moderate reliability and
promising validity. J Clin Epidemiol 2013;66:408–14.
30 Viswanathan M, Berkman ND, Dryden DM. AHRQ methods for
effective health care. assessing risk of bias and confounding
in observational studies of interventions or exposures: further
development of the RTI item bank. Rockville, MD: Agency for
Healthcare Research and Quality (US), 2013.
31 et alWells GA, Shea B, O'Connell D. The Newcastle‐Ottawa scale
(NOS) for assessing the quality of nonrandomised studies in
meta‐analyses. Available: http://www.ohri.ca/programs/clinical_
epidemiology/oxford.asp [Accessed 9 Jul 2019].
32 Scottish Intercollegiate Guidelines Network. Available: https://www.
sign.ac.uk/checklists-and-notes.html [Accessed 17 Oct 2019, 9 Jul
2020].
33 University of Montreal. Critical appraisal Worksheet. University of
Montreal, 2011. Available: https://guides.bib.umontreal.ca/uploads/
uploads/original/critical-appraisal-worksheet.pdf?1296211861
[Accessed 9 Jul 2020].
34 The STROBE Statement. Strengthening the reporting of
observational studies (cohort, case-control, and cross-sectional),
2007. Available: https://www.strobe-statement.org/index.php?id=
strobe-aims [Accessed 9 Jul 2020].
35 Public Health, Effective Public Health Practice Project (EPHPP).
Effective public healthcare panacea project. Quality assessment tool
for quantitative studies. Available: https://link.springer.com/content/
pdf/bbm%3A978-3-319-17284-2/1 [Accessed 9 Jul 2020].
36 Des Jarlais DC, Lyles C, Crepaz N, et al. Improving the reporting
quality of nonrandomized evaluations of behavioral and public
health interventions: the trend statement. Am J Public Health
2004;94:361–6. doi:10.2105/AJPH.94.3.361
37 Margetts BM, Vorster HH, Venter CS. Evidence-Based nutrition—
review of nutritional epidemiological studies. South African J Clin
Nutr 2002;15:68–73.
38 Zaza S, Wright-De Agüero LK, Briss PA, et al. Data collection
instrument and procedure for systematic reviews in the guide to
community preventive services. Task force on community preventive
services. Am J Prev Med 2000;18:44–74.
39 Downs SH, Black N. The feasibility of creating a checklist for the
assessment of the methodological quality both of randomised and
non-randomised studies of health care interventions. J Epidemiol
Community Health 1998;52:377–84.
40 Elwood JM. Critical appraisal of epidemiological studies and clinical
trials. Oxford University Press: Oxford, 1998.

